[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621745":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":45,"id":59,"slug":10,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":80,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Peking University Shenzhen Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Treatment group",null,[12],"Drug: Iruplinalkib tablets",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Iruplinalkib tablets","180mg, QD",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"FEN WANG","CONTACT","+86 13510331485","fina_wang@163.com",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Shenzhen","Guangdong","518000","China",{"type":33,"coordinates":34},"Point",[35,36],114.0683,22.54554,{"lat":36,"lon":35},[39],{"name":21,"role":22,"phone":40,"phoneExt":10,"email":24},"+86 13692291485",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Fen Wang","Associate chief physician",[46,48,50,52,54,56],{"name":47,"class":6},"Shenzhen People's Hospital",{"name":49,"class":6},"Longgang District People's Hospital of Shenzhen",{"name":51,"class":6},"Sun Yat-Sen University Cancer Center",{"name":53,"class":6},"Eighth Affiliated Hospital, Sun Yat-sen University",{"name":55,"class":6},"The First Affiliated Hospital of Guangzhou Medical University",{"name":57,"class":58},"People Hospital of New District Longhua Shenzhen","UNKNOWN","100621745",false,"NCT07374614","Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib","An Observational Study of the Efficacy and Safety of Iruplinalkib(WX-0593) in ALK-positive Advanced Lung Adenocarcinoma Following Lorlatinib Treatment","SAILOR","Inclusion Criteria:\n\n1. Population: Male or female patients aged ≥18 years.\n2. Diagnosis: Histologically or cytologically confirmed advanced lung adenocarcinoma.\n3. Molecular Status: Documentation of ALK rearrangement confirmed by a validated test (e.g., NGS, IHC, FISH).\n4. Prior Therapy: Prior treatment with lorlatinib (in any line of therapy), with documented disease progression or intolerance.\n5. Current Therapy: Initiated treatment with iruplinalkib in the real-world setting.\n6. Measurability: Presence of at least one evaluable lesion (measurable or non-measurable) for response assessment.\n7. Data Availability: availability of key clinical data (baseline characteristics, treatment history, and follow-up outcomes).\n\nExclusion Criteria:\n\n1. Lack of Exposure: Patients who never actually received iruplinalkib or took only a trivial amount (e.g., \\\u003C 1 week\u002Fcycle) before withdrawal for non-medical reasons.\n2. Wrong Diagnosis: Active malignancy of other histological types (excluding treated basal cell carcinoma, etc.).\n3. Confounding: Participation in another interventional clinical trial involving an investigational anti-tumor drug concurrently.\n4. Pregnancy: Pregnant or breastfeeding women.\n5. Data Quality: Missing critical medical records that preclude assessment of primary endpoints (e.g., unknown start date, unknown prior therapy).","ALL","18 Years",{"count":69,"type":70},20,"ESTIMATED","OBSERVATIONAL","This observational study aims to evaluate the real-world effectiveness and safety of iruplinalkib in patients with advanced ALK-positive lung adenocarcinoma who have progressed on or are intolerant to prior lorlatinib therapy. The results are expected to provide real-world evidence to inform clinical decision-making for this heavily pretreated patient population.",[74,75,76,77,78,79],"Non-Small Cell Lung Cancer","ALK","Iruplinalkib","Lorlatinib","Real-world Study","Observational Study",[76,81,82,83],"ALK-postive","Post-Lorlatinib","Advanced Lung Adenocarcinoma","2026-01-24",{"date":86,"type":87},"2026-01-29","ACTUAL",{"date":89,"type":70},"2026-01-31",{"date":91,"type":70},"2028-12-31",{"name":5,"class":6},1]